title: Constant drug dose in human immuno-deficiency virus-infected patients to induce long-term non-progressor status: bifurcation and controllability approach.
abstract: The authors propose a therapy consisting of a constant dosage of reverse transcription inhibitor and protease inhibitor to achieve long-term non-progressor (LTNP) status in human immuno-deficiency virus (HIV) patients. Based on the authors analyses of cytotoxic T lymphocyte precursor (CTLp) concentration at several equilibrium points and the bifurcation of these equilibrium points, they find that administration of drugs with an efficacy lower than a certain level induces a higher CTLp concentration. As a result, drug doses of moderate efficacy result in more patients with LTNP status than doses with high efficacy. In analyses of controllability, they show that a treatment of moderate efficacy is more efficient than one of very high efficacy in terms of controlling the immune system. Using simulations, they demonstrate that their proposed method results in LTNP status in HIV patients.
authors.affiliation: Department of Electrical Engineering, Hanyang University, Seoul 133-791, Korea.
authors.forename: Wonhee
authors.initials: W
authors.lastname: Kim
authors.forename: Han Byul
authors.initials: HB
authors.lastname: Chung
authors.forename: Chung Choo
authors.initials: CC
authors.lastname: Chung
mesh_terms: D003198:Computer Simulation; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D020276:HIV Long-Term Survivors; D006801:Humans; D008954:Models, Biological; D011480:Protease Inhibitors / Q000008:administration & dosage; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D049490:Systems Biology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors
references.citation: Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14464-9
references.pmid: 10588728
references.citation: J Theor Biol. 2006 Jan 21;238(2):368-82
references.pmid: 15993900
references.citation: Science. 2000 Nov 3;290(5493):946-9
references.pmid: 11184735
references.citation: Evolution. 2009 Sep;63(9):2326-39
references.pmid: 19486149
references.citation: Bioessays. 2002 Dec;24(12):1178-87
references.pmid: 12447982
references.citation: Proc Biol Sci. 2004 Jun 7;271(1544):1101-9
references.pmid: 15306358
references.citation: Hum Immunol. 2001 Jun;62(6):561-76
references.pmid: 11390031
references.citation: PLoS Comput Biol. 2009 Oct;5(10):e1000533
references.pmid: 19834532
references.citation: AIDS. 2000 Oct 20;14(15):2313-22
references.pmid: 11089619
references.citation: IEEE Trans Biomed Eng. 2006 Mar;53(3):380-6
references.pmid: 16532764
references.citation: IEEE Trans Biomed Eng. 2003 Nov;50(11):1213-20
references.pmid: 14619991
references.citation: Bull Math Biol. 2007 Aug;69(6):2027-60
references.pmid: 17450401
references.citation: AIDS. 2000 Jan 28;14(2):109-16
references.pmid: 10708280